BioProcess Insider Interviews

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
One on One Interviews - CEO Steve Burton talks to Bioprocess Insider editor Dan Stanton about Astrea Bioseparation’s streamlined strategy following its recent acquisition by KKR Gamma Biosciences. He also explains why, 30 years on, antibody makers continue to demand solutions to the bottlenecks in the downstream process, and how chemical and small molecule-based adsorbents can offer a more customized and cost-effective alternative to recombinant ligands and the ‘gold standard’ Protein A.